NPCE Stock Price, NeuroPace, Inc. Quote, Chart

Market Summary

USD8.09-0.47

Market Closed

-5.49%

NPCE Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Losses in recent quarter

NPCE Stock Price

View Fullscreen

NPCE RSI Chart

NPCE Valuation

Market Cap

232.7M

Price/Earnings (Trailing)

-7.39

Price/Sales (Trailing)

3.37

Price/Free Cashflow

-13.17

NPCE Price/Sales (Trailing)

NPCE Profitability

Return on Equity

-219.69%

Return on Assets

-31.87%

Free Cashflow Yield

-7.59%

NPCE Fundamentals

NPCE Revenue

Revenue (TTM)

69.1M

Rev. Growth (Yr)

25.23%

Rev. Growth (Qtr)

0.62%

NPCE Earnings

Earnings (TTM)

-31.5M

Earnings Growth (Yr)

13.98%

Earnings Growth (Qtr)

-43.95%

Breaking Down NPCE Revenue

Last 7 days

-4.8%

Last 30 days

-41.2%

Last 90 days

-50.8%

Trailing 12 Months

90.8%

How does NPCE drawdown profile look like?

NPCE Financial Health

Current Ratio

6.43

Debt/Equity

4.05

Debt/Cashflow

-0.3

NPCE Investor Care

Shares Dilution (1Y)

13.24%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	69.1M	0	0	0
2023	48.6M	54.9M	60.2M	65.4M
2022	45.3M	42.9M	43.7M	45.5M
2021	42.4M	47.4M	44.9M	45.2M
2020	0	0	0	41.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuroPace, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	orbimed advisors llc	sold	-65,576	14.03	-4,674	-
May 02, 2024	orbimed advisors llc	sold	-123,876	14.01	-8,842	-
May 01, 2024	orbimed advisors llc	sold	-219,974	14.02	-15,690	-
Apr 24, 2024	orbimed advisors llc	sold	-25,040	14.06	-1,781	-
Apr 23, 2024	orbimed advisors llc	sold	-311,393	14.29	-21,791	-
Apr 22, 2024	orbimed advisors llc	sold	-345,756	14.05	-24,609	-
Apr 19, 2024	orbimed advisors llc	sold	-255,907	14.02	-18,253	-
Apr 18, 2024	orbimed advisors llc	sold	-36,879	14.06	-2,623	-
Apr 17, 2024	orbimed advisors llc	sold	-4,245	14.15	-300	-
Apr 16, 2024	orbimed advisors llc	sold	-197,107	14.01	-14,069	-

Which funds bought or sold NPCE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	95.57	570,937	950,572	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-57.04	-148,021	180,919	-%
May 15, 2024	MORGAN STANLEY	added	0.95	7,418,590	32,788,600	-%
May 15, 2024	STATE STREET CORP	added	11.69	147,864	491,713	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-66.12	-140,427	107,580	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	1,845,930	1,845,930	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	1,393	47,074	49,672	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	11,571,500	52,852,400	0.97%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-2.06	88,731	438,240	0.01%

Are Funds Buying or Selling NPCE?

Are funds buying NPCE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NPCE

No. of Funds

Unveiling NeuroPace, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	orbimed advisors llc	15.2%	4,003,967	SC 13G/A
Feb 14, 2024	kck ltd.	21.3%	5,593,773	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	morgan stanley	9.4%	2,460,716	SC 13G/A
Feb 02, 2024	soleus private equity fund i, l.p.	2.2%	582,186	SC 13G/A
Feb 14, 2023	orbimed advisors llc	16.1%	4,012,281	SC 13G/A
Feb 14, 2023	soleus private equity fund i, l.p.	2.4%	592,186	SC 13G/A
Feb 10, 2023	morgan stanley	8.8%	2,188,593	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G
Nov 23, 2022	accelmed partners ii l.p.	17.8%	4,432,948	SC 13D/A

Recent SEC filings of NeuroPace, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 18, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading

Peers (Alternatives to NeuroPace, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

NeuroPace, Inc. News

Latest updates

NeuroPace, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	0.6%	18.00	18.00	16.00	17.00	14.00	13.00	11.00	10.00	11.00	11.00	10.00	13.00	11.00	11.00	13.00	8.00	10.00
Gross Profit	-1.5%	13.00	14.00	12.00	12.00	10.00	9.00	8.00	7.00	8.00	8.00	8.00	9.00	8.00	8.00	10.00	5.00	7.00
Operating Expenses	12.3%	21.00	19.00	18.00	20.00	19.00	19.00	18.00	18.00	18.00	17.00	14.00	14.00	12.00	11.00	11.00	9.00	13.00
S&GA Expenses	14.3%	15.00	13.00	13.00	14.00	13.00	14.00	13.00	13.00	12.00	12.00	9.00	10.00	8.00	7.00	7.00	6.00	8.00
R&D Expenses	7.6%	6.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	5.00
Interest Expenses	1.0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	3.00
Net Income	-44.0%	-8.93	-6.20	-7.26	-9.12	-10.37	-11.15	-11.78	-12.69	-11.46	-10.69	-8.08	-8.49	-8.81	-4.62	-4.13	-8.79	-6.74
Net Income Margin	9.5%	-0.46*	-0.50*	-0.63*	-0.77*	-0.95*	-1.03*	-1.07*	-1.00*	-0.85*	-0.80*	-0.67*	-0.55*	-	-	-	-	-
Free Cashflow	-126.3%	-7.63	-3.37	-2.27	-4.40	-9.83	-8.00	-6.93	-10.86	-11.71	-8.35	-4.63	-6.07	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-8.2%	99.00	108	99.00	102	106	114	120	119	129	134	141	147	50.00	56.00
Current Assets	-9.1%	84.00	93.00	84.00	87.00	90.00	98.00	104	112	122	133	140	146	47.00	55.00
Cash Equivalents	-27.3%	13.00	18.00	10.00	8.00	7.00	7.00	6.00	6.00	7.00	19.00	27.00	31.00	14.00	27.00
Inventory	1.8%	11.00	11.00	10.00	10.00	11.00	10.00	9.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00
Net PPE	4.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00
Liabilities	-2.9%	85.00	87.00	83.00	81.00	79.00	79.00	77.00	66.00	66.00	60.00	60.00	58.00	65.00	62.00
Current Liabilities	-19.2%	13.00	16.00	13.00	12.00	10.00	11.00	9.00	11.00	12.00	9.00	9.00	8.00	11.00	10.00
Long Term Debt	1.9%	58.00	57.00	56.00	55.00	54.00	53.00	52.00	51.00	50.00	50.00	50.00	49.00	50.00	51.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	2.00
LT Debt, Non Current	-100.0%	-	57.00	56.00	55.00	54.00	53.00	52.00	51.00	50.00	50.00	50.00	49.00	50.00	51.00
Shareholder's Equity	-30.6%	14.00	21.00	16.00	21.00	27.00	35.00	43.00	53.00	63.00	74.00	82.00	89.00	-	-
Retained Earnings	-1.8%	-512	-503	-497	-490	-481	-470	-459	-447	-435	-423	-413	-405	-396	-387
Additional Paid-In Capital	0.5%	527	524	514	512	509	507	504	502	499	498	495	494	240	240
Shares Outstanding	3.2%	29.00	28.00	26.00	26.00	25.00	25.00	25.00	25.00	24.00	24.00	24.00	18.00	-	-
Float	-	-	-	-	66.00	-	-	-	50.00	-	-	-	198	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-125.3%	-7,528	-3,341	-2,260	-4,402	-9,698	-7,900	-6,900	-10,700	-11,400	-8,200	-4,450	-6,050	-5,900	-6,400	-5,400	-3,300	-6,500
Share Based Compensation	7.8%	2,540	2,357	2,421	2,655	2,125	2,076	2,182	2,603	1,488	1,876	1,107	1,103	202	487	301	290	301
Cashflow From Investing	-30.9%	2,396	3,468	4,191	5,300	10,068	8,898	6,969	8,236	-306	-154	-190	-80,017	-5,035	-10,046	-250	-	-471
Cashflow From Financing	-99.1%	72.00	8,214	-27.00	195	-255	-138	-8.00	635	1.00	911	-	103,193	-1,578	-279	38,815	3,953	12,520
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NPCE Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 18,124	$ 14,472
Cost of goods sold	4,781	4,100
Gross profit	13,343	10,372
Operating expenses
Research and development	5,784	5,263
Selling, general and administrative	15,104	13,428
Total operating expenses	20,888	18,691
Loss from operations	(7,545)	(8,319)
Interest income	827	726
Interest expense	(2,258)	(1,965)
Other income (expense), net	51	(817)
Net loss	(8,925)	(10,375)
Comprehensive loss	$ (8,925)	$ (10,375)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.32)	$ (0.41)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.32)	$ (0.41)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	28,285,176	25,097,262
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	28,285,176	25,097,262

NPCE Balance Sheet

2024-03-31

Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 12,998	$ 18,058
Short-term investments	45,947	48,396
Accounts receivable	11,631	12,314
Inventory	11,416	11,214
Prepaid expenses and other current assets	2,262	2,737
Total current assets	84,254	92,719
Property and equipment, net	1,048	1,003
Operating lease right-of-use asset	13,027	13,405
Restricted cash	122	122
Deferred offering costs	387	387
Other assets	15	15
Total assets	98,853	107,651
Current liabilities
Accounts payable	3,268	2,332
Accrued liabilities	7,290	11,180
Operating lease liability	1,683	1,627
Deferred revenue	869	1,090
Total current liabilities	13,110	16,229
Long-term debt	58,039	56,954
Operating lease liability, net of current portion	13,363	13,814
Total liabilities	84,512	86,997
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 28,717,452 and 27,823,465 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	29	28
Additional paid-in capital	527,046	524,435
Accumulated deficit	(512,734)	(503,809)
Total stockholders’ equity	14,341	20,654
Total liabilities and stockholders’ equity	$ 98,853	$ 107,651

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

CEO	Mr. Joel D. Becker
WEBSITE	neuropace.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	169

NeuroPace, Inc. Frequently Asked Questions

What is the ticker symbol for NeuroPace, Inc.? What does NPCE stand for in stocks?

NPCE is the stock ticker symbol of NeuroPace, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroPace, Inc. (NPCE)?

As of Fri May 17 2024, market cap of NeuroPace, Inc. is 232.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NPCE stock?

You can check NPCE's fair value in chart for subscribers.

What is the fair value of NPCE stock?

You can check NPCE's fair value in chart for subscribers. The fair value of NeuroPace, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroPace, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NPCE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroPace, Inc. a good stock to buy?

The fair value guage provides a quick view whether NPCE is over valued or under valued. Whether NeuroPace, Inc. is cheap or expensive depends on the assumptions which impact NeuroPace, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NPCE.

What is NeuroPace, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NPCE's PE ratio (Price to Earnings) is -7.39 and Price to Sales (PS) ratio is 3.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NPCE PE ratio will change depending on the future growth rate expectations of investors.